LLW-018

• Description:

  LLW-018 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 2.61 nM. LLW-018 can interrupt PD-1/PD-L1 interaction with an IC50 value of 0.88 μM by cell-based PD-1/PD-L1 blockade bioassays. LLW-018 has the potential for immunotherapy research[1].

• UNSPSC:

  12352005

• Target:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/llw-018.html

• Smiles:

  OCC (CO) NCC1=CC=C (NC2=NSC3=C2C=CC=C3C4=C (C) C (COC5=C (Cl) C=C (CNC (CO) CO) C=C5) =CC=C4) C (Cl) =C1

• Molecular Formula:

  C35H38Cl2N4O5S

• Molecular Weight:

  697.67

• References & Citations:

  [1]Hanxun Wang, et al. Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction. Eur J Med Chem. 2024 Sep 5:275:116622.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  3049369-11-8